Advances in HIV microbicide development

Future Medicinal Chemistry

Volumn 3, Issue 16, 2011, Pages 2101-2116

  Olsen, Joanna S ^a   Easterhoff, David ^a   Dewhurst, Stephen ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; BETA DEFENSIN; C 31G; CARBOPOL 974P; CARRAGEENAN; CELLULOSE SULFATE; CHEMOKINE RECEPTOR CCR5; DAPIVIRINE; ELAFIN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LACTOFERRIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MARAVIROC; MICROBICIDE; NONOXINOL; PRO 2000; PROGESTERONE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SPERMIDINE; SPERMINE; TENOFOVIR; UNCLASSIFIED DRUG; VIVAGEL;

ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; EPITHELIUM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RECTUM MUCOSA; REVIEW; SEXUAL INTERCOURSE; SPERM; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX MUCOSA; VAGINA FLORA; VIRION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; MUCOUS MEMBRANE;

EID: 81855183802     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.153     Document Type: Review

References (133)

1. UNAIDS. Report on the Global AIDS Epidemic 2010. Joint UN Programme on HIV/AIDS, Geneva, Switzerland (2010).
2. Mesquita PM, Cheshenko N, Wilson SS et al. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: Model of microbicide safety. J. Infect. Dis. 200(4), 599-608 (2009).
3. Stafford MK, Ward H, Flanagan A et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17(4), 327-331 (1998).
4. Kaushic C, Ferreira VH, Kafka JK, Nazli A. HIV infection in the female genital tract: discrete influence of the local mucosal microenvironment. Am. J. Reprod. Immunol. 63(6), 566-575 (2010).
5. Wira CR, Grant-Tschudy KS, Crane- Godreau MA. Epithelial cells in the female reproductive tract: A central role as sentinels of immune protection. Am. J. Reprod. Immunol. 53(2), 65-76 (2005).
6. Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: Mediators of cellular immunity are concentrated in the cervical transformation zone. Biol. Reprod. 73(6), 1253-1263 (2005).
7. Li Q, Estes JD, Schlievert PM et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 458(7241), 1034-1038 (2009).
8. Kell PD, Barton SE, Edmonds DK, Boag FC. HIV infection in a patient with Meyer-Rokitansky-Kuster-Hauser 1 UNAIDS. Report on the Global AIDS Epidemic 2010. Joint UN Programme on HIV/AIDS, Geneva, Switzerland (2010).
9. Hladik F, Mcelrath MJ. Setting the stage: host invasion by HIV. Nat. Rev. Immunol. 8(6), 447-457 (2008).
10. King AE, Critchley HO, Kelly RW. Presence of secretory leukocyte protease inhibitor in human endometrium and first trimester decidua suggests an antibacterial protective role. Mol. Hum. Reprod. 6(2), 191-196 (2000).
11. Mcneely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: A human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J. Clin. Invest. 96(1), 456-464 (1995).
12. Lai SK, Hida K, Shukair S et al. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J. Virol. 83(21), 11196-11200 (2009).
13. Moriuchi M, Moriuchi H. A milk protein lactoferrin enhances human T cell leukemia virus type I and suppresses HIV-1 infection. J. Immunol. 166(6), 4231-4236 (2001).
14. Sun L, Finnegan CM, Kish-Catalone T et al. Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J. Virol. 79(22), 14318-14329 (2005).
15. Iqbal SM, Ball TB, Levinson P et al. Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 23(13), 1669-1677 (2009).
16. Ghosh M, Shen Z, Fahey JV, Cu-Uvin S, Mayer K, Wira CR. Trappin-2/elafin: A novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology 129(2), 207-219 (2010).
17. Trabattoni D, Caputo SL, Maffeis G et al. Human alpha defensin in HIV-exposed but uninfected individuals. J. Acquir. Immune Defic. Syndr. 35(5), 455-463 (2004).
18. Kuhn L, Trabattoni D, Kankasa C et al. Alpha-defensins in the prevention of HIV transmission among breastfed infants. J. Acquir. Immune Defic. Syndr. 39(2), 138-142 (2005).
19. Hill JA, Anderson DJ. Human vaginal leukocytes and the effects of vaginal fluid on lymphocyte and macrophage defense functions. Am. J. Obstet. Gynecol. 166(2), 720-726 (1992).
20. Klebanoff SJ, Coombs RW. Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J. Exp. Med. 174(1), 289-292 (1991).
21. Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L. Innate and adaptive immunity in female genital tract: Cellular responses and interactions. Immunol. Rev. 206, 306-335 (2005).
22. 8+ T cells. Science 270(5243), 1811-1815 (1995).
23. 4+ T cells during primary immune responses. Proc. Natl Acad. Sci. USA 100(25), 15006-15010 (2003).
24. Fish EN. The x-files in immunity: sex-based differences predispose immune responses. Nat. Rev. Immunol. 8(9), 737-744 (2008).
25. 8+ CTL activity within the human female reproductive tract: Influence of stage of the menstrual cycle and menopause. J. Immunol. 158(6), 3017-3027 (1997).
26. Kutteh WH, Prince SJ, Hammond KR, Kutteh CC, Mestecky J. Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation. Clin. Exp. Immunol. 104(3), 538-542 (1996).
27. 8+ T cell viral-specific effector function and induces herpes simplex virus type 1 reactivation. J. Immunol. 181(2), 969-975 (2008).
28. Laskarin G, Strbo N, Sotosek V et al. Progesterone directly and indirectly affects perforin expression in cytolytic cells. Am. J. Reprod. Immunol. 42(5), 312-320 (1999).
29. Smith SM, Baskin GB, Marx PA. Estrogen protects against vaginal transmission of simian immunodeficiency virus. J. Infect. Dis. 182(3), 708-715 (2000).
30. Gupta S, Kumar N, Singhal N, Manektala U, Jain S, Sodhani P. Cytohormonal and morphological alterations in cervicovaginal smears of postmenopausal women on hormone replacement therapy. Diagn. Cytopathol. 34(10), 676-681 (2006).
31. Marx PA, Spira AI, Gettie A et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 2(10), 1084-1089 (1996).
32. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr. Rev. 31(1), 79-97 (2010).
33. Miller L, Patton DL, Meier A, Thwin SS, Hooton TM, Eschenbach DA. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet. Gynecol. 96(3), 431-439 (2000).
34. Wieser F, Hosmann J, Tschugguel W, Czerwenka K, Sedivy R, Huber JC. Progesterone increases the number of Langerhans cells in human vaginal epithelium. Fertil. Steril. 75(6), 1234-1235 (2001).
35. Iqbal SM, Kaul R. Mucosal innate immunity as a determinant of HIV susceptibility. Am. J. Reprod. Immunol. 59(1), 44-54 (2008).
36. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: A systematic review and meta-analysis. Sex. Transm. Dis. 35(11), 946-959 (2008).
37. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20(1), 73-83 (2006).
38. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat. Rev. Microbiol. 1(1), 25-34 (2003).
39. Neutra MR. Interactions of viruses and microparticles with apical plasma membranes of M cells: Implications for human immunodeficiency virus transmission. J. Infect. Dis. 179(Suppl. 3), S441-S443 (1999).
40. Lackner AA, Mohan M, Veazey RS. The gastrointestinal tract and AIDS pathogenesis. Gastroenterology 136(6), 1965-1978 (2009).
41. Garcia-Lerma JG, Aung W, Cong ME et al. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J. Virol. 85(13), 6610-6617 (2011).
42. Tevi-Benissan C, Belec L, Levy M et al. In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin. Diagn. Lab. Immunol. 4(3), 367-374 (1997).
43. Munch J, Rucker E, Standker L et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 131(6), 1059-1071 (2007).
44. Patel S, Hazrati E, Cheshenko N et al. Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J. Infect. Dis. 196(9), 1394-1402 (2007).
45. Keller MJ, Mesquita PM, Torres NM et al. Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: Implications for syndrome. J. R. Soc. Med. 85(11), 706-707 (1992).
46. Berlier W, Cremel M, Hamzeh H et al. Seminal plasma promotes the attraction of Langerhans cells via the secretion of CCL20 by vaginal epithelial cells: Involvement in the sexual transmission of HIV. Hum. Reprod. 21(5), 1135-1142 (2006).
47. Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA. Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol. Hum. Reprod. 13(7), 491-501 (2007).
48. Mcneely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90(3), 1141-1149 (1997).
49. Ohlsson K, Bjartell A, Lilja H. Secretory leucocyte protease inhibitor in the male genital tract: PSA-induced proteolytic processing in human semen and tissue localization. J. Androl. 16(1), 64-74 (1995).
50. Roan NR, Munch J, Arhel N et al. The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. J. Virol. 83(1), 73-80 (2009).
51. Kim KA, Yolamanova M, Zirafi O et al. Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology 7, 55 (2010).
52. Clumeck N, Taelman H, Hermans P, Piot P, Schoumacher M, De Wit S. A cluster of HIV infection among heterosexual people without apparent risk factors. N. Engl. J. Med. 321(21), 1460-1462 (1989).
53. Neildez O, Le Grand R, Cheret A et al. Variation in virological parameters and antibody responses in macaques after atraumatic vaginal exposure to a pathogenic primary isolate of SIVmac251. Res. Virol. 149(1), 53-68 (1998).
54. Miller CJ, Marthas M, Torten J et al. Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. J. Virol. 68(10), 6391-6400 (1994).
55. Norvell MK, Benrubi GI, Thompson RJ. Investigation of microtrauma after sexual intercourse. J. Reprod. Med. 29(4), 269-271 (1984).
56. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 3(1), 42-47 (1997).
57. Dezzutti CS, Guenthner PC, Cummins JE Jr et al. Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J. Infect. Dis. 183(8), 1204-1213 (2001).
58. 4+ cells: Implications for mechanisms of sexual transmission. J. Infect. Dis. 188(10), 1473-1482 (2003).
59. Yeaman GR, Asin S, Weldon S et al. Chemokine receptor expression in the human ectocervix: Implications for infection by the human immunodeficiency virus-type I. Immunology 113(4), 524-533 (2004).
60. Furuta Y, Eriksson K, Svennerholm B et al. Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120. Proc. Natl Acad. Sci. USA 91(26), 12559-12563 (1994).
61. Turville SG, Cameron PU, Handley A et al. Diversity of receptors binding HIV on dendritic cell subsets. Nat. Immunol. 3(10), 975-983 (2002).
62. Bouschbacher M, Bomsel M, Verronese E et al. Early events in HIV transmission through a human reconstructed vaginal mucosa. AIDS 22(11), 1257-1266 (2008).
63. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. 74(13), 6087-6095 (2000).
64. 4+ T cells. Nature 434(7037), 1148-1152 (2005).
65. 4+ T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)- infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J. Virol. 76(19), 9868-9876 (2002).
66. 4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc. Natl Acad. Sci. USA 101(15), 5640-5645 (2004).
67. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464(7286), 217-223 (2010).
68. Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect. Dis. 8(11), 685-697 (2008).
69. Degruttola V, Seage GR, 3rd, Mayer KH, Horsburgh CR, Jr. Infectiousness of HIV between male homosexual partners. J. Clin. Epidemiol. 42(9), 849-856 (1989).
70. Downs AM, De Vincenzi I. Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. European study group in heterosexual transmission of HIV. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11(4), 388-395 (1996).
71. Morrow KM, Hendrix C. Clinical evaluation of microbicide formulations. Antiviral Res. 88(Suppl. 1), S40-S46 (2010).
72. Hoffman IF, Taha TE, Padian NS et al. Nonoxynol-9 100 mg gel: Multi-site safety study from sub-Saharan Africa. AIDS 18(16), 2191-2195 (2004).
73. Peterson L, Nanda K, Opoku BK et al. SAVVY (C31G) gel for prevention of HIV infection in women: A Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2(12), e1312 (2007).
74. Feldblum PJ, Adeiga A, Bakare R et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: A randomized controlled trial in Nigeria. PLoS One 3(1), e1474 (2008).
75. 4+ cells. Science 240(4852), 646-649 (1988).
76. O'Loughlin J, Millwood IY, Mcdonald HM, Price CF, Kaldor JM, Paull JR. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): A dose ranging, phase I study. Sex. Transm. Dis. 37(2), 100-104 (2010).
77. Sachdev DD, Zerhouni-Layachi B, Ortigoza M et al. The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes. J. Acquir. Immune Defic. Syndr. 51(2), 125-129 (2009).
78. Callahan LN, Phelan M, Mallinson M, Norcross MA. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J. Virol. 65(3), 1543-1550 (1991).
79. Mccormack S, Ramjee G, Kamali A et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): A phase 3, randomised, double-blind, parallel-group trial. Lancet 376(9749), 1329-1337 (2010).
80. Van Damme L, Govinden R, Mirembe FM et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359(5), 463-472 (2008).future microbicide clinical trials. PLoS One 5(1), e8781 (2010).
81. Keele BF, Giorgi EE, Salazar-Gonzalez JF et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105(21), 7552-7557 (2008).
82. Veazey RS, Ketas TJ, Dufour J et al. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J. Infect. Dis. 202(5), 739-744 (2010).
83. Lederman MM, Veazey RS, Offord R et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306(5695), 485-487 (2004).
84. Veazey RS, Klasse PJ, Schader SM et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438(7064), 99-102 (2005).
85. Neff CP, Kurisu T, Ndolo T, Fox K, Akkina R. A Topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One 6(6), e20209 (2011).
86. Schader SM, Colby-Germinario SP, Schachter JR, Xu H, Wainberg MA. Synergy against drug resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination. AIDS 25(13), 1585-1594 (2011).
87. Tsai CC, Emau P, Jiang Y et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res. Hum. Retroviruses 19(7), 535-541 (2003).
88. Olmsted SS, Dubin NH, Cone RA, Moench TR. The rate at which human sperm are immobilized and killed by mild acidity. Fertil. Steril. 73(4), 687-693 (2000).
89. Abdool Karim SS, Richardson BA, Ramjee G et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25(7), 957-966 (2011).
90. Antonio MA, Hillier SL. DNA fingerprinting of Lactobacillus crispatus strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. J. Clin. Microbiol. 41(5), 1881-1887 (2003).
91. Patton DL, Cosgrove Sweeney YT, Antonio MA, Rabe LK, Hillier SL. Lactobacillus crispatus capsules: single-use safety study in the Macaca nemestrina model. Sex. Transm. Dis. 30(7), 568-570 (2003).
92. Liu X, Lagenaur LA, Simpson DA et al. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob. Agents Chemother. 50(10), 3250-3259 (2006).
93. Pusch O, Kalyanaraman R, Tucker LD, Wells JM, Ramratnam B, Boden D. An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli. AIDS 20(15), 1917-1922 (2006).
94. Chang TL, Chang CH, Simpson DA et al. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc. Natl Acad. Sci. USA 100(20), 11672-11677 (2003).
95. Vangelista L, Secchi M, Liu X et al. Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers. Antimicrob. Agents Chemother. 54(7), 2994-3001 (2010).
96. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996), 1168-1174 (2010).
97. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, Mccullagh SD. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int. J. Pharm. 325(1-2), 82-89 (2006).
98. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, Mccullagh SD. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J. Antimicrob. Chemother. 56(5), 954-956 (2005).
99. Malonza IM, Mirembe F, Nakabiito C et al. Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS 19(18), 2157-2163 (2005).
100. Bentley ME, Fullem AM, Tolley EE et al. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am. J. Public Health 94(7), 1159-1164 (2004).
101. Rohan LC, Sassi AB. Vaginal drug delivery systems for HIV prevention. AAPS J. 11(1), 78-87 (2009).
102. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ. Advances in microbicide vaginal rings. Antiviral Res. 88(Suppl. 1), S30-S39 (2010).
103. Nel A, Smythe S, Young K et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J. Acquir. Immune Defic. Syndr. 51(4), 416-423 (2009).
104. Romano J, Variano B, Coplan P et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res. Hum. Retroviruses 25(5), 483-488 (2009).
105. Hardy E, Hebling EM, Sousa MH, Almeida AF, Amaral E. Delivery of microbicides to the vagina: difficulties reported with the use of three devices, adherence to use and preferences. Contraception 76(2), 126-131 (2007).
106. Cu Y, Saltzman WM. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol. Pharm. 6(1), 173-181 (2009).
107. Cone RA. Barrier properties of mucus. Adv. Drug Deliv. Rev. 61(2), 75-85 (2009).
108. Clark MR, Aliyar HA, Lee CW et al. Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles. Int. J. Pharm. 413(1-2), 10-18 (2011).
109. Sluis-Cremer N, Moore K, Radzio J, Sonza S, Tachedjian G. N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. AIDS 24(2), 317-319 (2010).
110. Hachiya A, Kodama EN, Schuckmann MM et al. K70Q adds high-level tenofovir resistance to 'Q151M complex' HIV reverse transcriptase through the enhanced discrimination mechanism. PLoS One 6(1), e16242 (2011).
111. Gantlett KE, Weber JN, Sattentau QJ. Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides. Antiviral Res. 75(3), 188-197 (2007).
112. Wang Y, Abel K, Lantz K, Krieg AM, Mcchesney MB, Miller CJ. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J. Virol. 79(22), 14355-14370 (2005).
113. Doncel GF, Clark MR. Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers. Antiviral Res. 88(Suppl. 1), S10-S18 (2010).
114. Wege AK, Melkus MW, Denton PW, Estes JD, Garcia JV. Functional and phenotypic characterization of the humanized BLT mouse model. Curr. Top. Microbiol. Immunol. 324, 149-165 (2008).
115. Denton PW, Estes JD, Sun Z et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5(1), e16 (2008).
116. Denton PW, Krisko JF, Powell DA et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One 5(1), e8829 (2010).
117. Denton PW, Othieno F, Martinez-Torres F et al. Topically applied 1% tenofovir in humanized BLT mice using the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection validating the BLT model for the evaluation of new microbicide candidates. J. Virol. doi:10.1128/JVI.00537-11 (2011) (Epub ahead of print).
118. Lackman-Smith C, Osterling C, Luckenbaugh K et al. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob. Agents Chemother. 52(5), 1768-1781 (2008).
119. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 5(2), e9310 (2010).
120. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J. Virol. 74(12), 5577-5586 (2000).
121. Bestman-Smith J, Desormeaux A, Tremblay MJ, Bergeron MG. Targeting cell-free HIV and virally-infected cells with anti-HLA-DR immunoliposomes containing amphotericin B. AIDS 14(16), 2457-2465 (2000).
122. Kaplan JC, Crawford DC, Durno AG, Schooley RT. Inactivation of human immunodeficiency virus by Betadine. Infect. Control 8(10), 412-414 (1987).
123. Galen BT, Martin AP, Hazrati E et al. A comprehensive murine model to evaluate topical vaginal microbicides: Mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J. Infect. Dis. 195(9), 1332-1339 (2007).
124. Trifonova RT, Bajpai M, Pasicznyk JM, Chandra N, Doncel GF, Fichorova RN. Biomarkers of leukocyte traffic and activation in the vaginal mucosa. Biomarkers 12(6), 608-622 (2007).
125. Cummins JE Jr, Doncel GF. Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety. Sex. Transm. Dis. 36(Suppl. 3), S84-S91 (2009).
126. Cranage M, Sharpe S, Herrera C et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 5(8), e157; discussion e157 (2008).
127. Kenney J, Aravantinou M, Singer R et al. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 6(1), e15835 (2011).
128. Anton P, Cranston R, Carballo-Dieguez A et al. RMP-02/MTN-006: A Phase 1 placebo-controlled trial of rectally applied 1% vaginal TFV gel with comparison to oral TDF. Presented at: Conference on Retroviruses and Oppurtunistic Infections. Boston, MA, USA, 27 February-2 March 2011.
129. Fuchs EJ, Lee LA, Torbenson MS et al. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J. Infect. Dis. 195(5), 703-710 (2007).
130. Hendrix CW, Fuchs EJ, Macura KJ et al. Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates. Clin. Pharmacol. Ther. 83(1), 97-105 (2008).
131. Anderson DJ, Politch JA, Nadolski AM, Blaskewicz CD, Pudney J, Mayer KH. Targeting Trojan Horse leukocytes for HIV prevention. AIDS 24(2), 163-187 (2010).
132. Szekeres-Bartho J, Wegmann TG. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. J. Reprod. Immunol. 31(1-2), 81-95 (1996).
133. Kersh EN, Adams DR, Youngpairoj AS et al. T cell chemo-vaccination effects after repeated mucosal SHIV exposures and oral pre-exposure prophylaxis. PLoS One 6(4), e19295 (2011).